Related Experiment Videos

[Is a new therapeutic class justified in the treatment of type 2 diabetes?]

S Halimi1

  • 1Service d'Endocrinologie - Diabétologie - Nutrition, CHU de Grenoble, F - 38043 Grenoble Cedex, France.

Annales D'Endocrinologie
|May 31, 2002
PubMed

Insights

Early treatment of type 2 diabetes (T2D) with hyperglycaemia is crucial. Combining metformin or sulfonylureas with thiazolidinediones offers improved glycaemic control without increased hypoglycaemia risk.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) is linked to microvascular and macrovascular complications.
  • Early intensive hyperglycaemia treatment, as shown by UKPDS, reduces these complications.
  • Current T2D management faces challenges like delayed diagnosis and treatment adherence.

Purpose of the Study:

  • To evaluate the role of thiazolidinediones in T2D management.
  • To assess the benefits of combining thiazolidinediones with existing oral antidiabetic agents.
  • To improve early glycaemic control and mitigate risks associated with intensive therapy.

Main Methods:

  • Review of existing literature and clinical trial data on T2D treatments.
  • Analysis of the mechanisms of action for thiazolidinediones.
  • Comparison of combination therapy outcomes versus monotherapy.

Main Results:

  • Existing oral antidiabetic agents (sulfonylureas, metformin, alpha-glucosidase inhibitors) have limitations.
  • Thiazolidinediones target key T2D physiopathological pathways.
  • Combination therapy with metformin or sulfonylurea and thiazolidinediones shows promise for early, effective glycaemic control.

Conclusions:

  • Thiazolidinediones represent a valuable addition to T2D pharmacotherapy.
  • Combining metformin or sulfonylureas with thiazolidinediones can achieve better glycaemic control.
  • This combination strategy may reduce hypoglycaemia risk in early-stage T2D management.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...